A Poncelet1, L Ruelle2, D Konopnicki2, V Y Miendje Deyi3, N Dauby2. 1. Infectious Diseases Department, Saint-Pierre University Hospital, Université Libre de Bruxelles, rue aux Laines, 105, 1000 Bruxelles, Belgium. Electronic address: arthur.poncelet@ulb.ac.be. 2. Infectious Diseases Department, Saint-Pierre University Hospital, Université Libre de Bruxelles, rue aux Laines, 105, 1000 Bruxelles, Belgium. 3. Microbiology Department, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium.
Abstract
Saccharomyces cerevisiae fungemia: risk factors, outcome and links with S. boulardii-containing probiotic administration. OBJECTIVE: The aim of our study was to review cases of S. cerevisiae fungemia along with the corresponding risk factors (including S. boulardii probiotic intake), treatment and outcomes. PATIENTS AND METHODS: Retrospective study (2005-2017) of S. cerevisiae fungemia. All the data were extracted from medical files. RESULTS: We identified 10 patients with S. cerevisiae fungemia. Mean age was 59.4 years (range 21-88). Four fifths (80%) were on total parenteral or enteral nutrition, 70% had a central venous line, and 30% were admitted in an Intensive Care Unit (ICU). S. boulardii-containing probiotic prescription was identified in 6 subjects. Three patients with no risk factors such as ICU or central venous catheter were 80 years old or more. Mortality rate was 50%. CONCLUSION: S. cerevisiae fungemia is a rare but life-threatening infection, associated with intake of probiotics containing S. boulardii. Besides classical risk factors, older age should be a contraindication for these probiotics.
Saccharomyces cerevisiaefungemia: risk factors, outcome and links with S. boulardii-containing probiotic administration. OBJECTIVE: The aim of our study was to review cases of S. cerevisiaefungemia along with the corresponding risk factors (including S. boulardii probiotic intake), treatment and outcomes. PATIENTS AND METHODS: Retrospective study (2005-2017) of S. cerevisiaefungemia. All the data were extracted from medical files. RESULTS: We identified 10 patients with S. cerevisiaefungemia. Mean age was 59.4 years (range 21-88). Four fifths (80%) were on total parenteral or enteral nutrition, 70% had a central venous line, and 30% were admitted in an Intensive Care Unit (ICU). S. boulardii-containing probiotic prescription was identified in 6 subjects. Three patients with no risk factors such as ICU or central venous catheter were 80 years old or more. Mortality rate was 50%. CONCLUSION:S. cerevisiaefungemia is a rare but life-threatening infection, associated with intake of probiotics containing S. boulardii. Besides classical risk factors, older age should be a contraindication for these probiotics.
Authors: Alexandra Imre; Renátó Kovács; Zoltán Tóth; László Majoros; Zsigmond Benkő; Walter P Pfliegler; István Pócsi Journal: J Fungi (Basel) Date: 2022-05-18